Guillain-Barre Syndrome Market Report 2026

The guillain-barre syndrome market size has grown strongly in recent years. It will grow from $0.64 billion in 2025 to $0.67 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to improved recognition of autoimmune neurological conditions, expansion of hospital-based neurology departments, increased availability of immunotherapy treatments, rising post-infectious complication cases, better critical care infrastructure.

The guillain-barre syndrome market size is expected to see strong growth in the next few years. It will grow to $0.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to increasing investments in neurology research, rising demand for advanced immunomodulatory therapies, expansion of specialized rehabilitation services, growing use of digital neurological assessment tools, increasing focus on early intervention strategies. Major trends in the forecast period include increasing use of intravenous immunoglobulin therapies, rising adoption of plasma exchange procedures, growing focus on early neurological diagnosis, expansion of specialized neurology care centers, enhanced monitoring of autoimmune neurological disorders.

The increasing risk of immunological diseases is expected to drive the growth of the Guillain-Barré syndrome market in the coming years. Immunological diseases are conditions in which the immune system becomes overactive, underactive, or improperly directed, resulting in disorders such as autoimmune diseases, allergies, or immunodeficiencies. The prevalence of immunological diseases is rising due to factors including environmental changes, lifestyle patterns, improved diagnostic capabilities, and genetic predisposition. These conditions can trigger Guillain-Barré syndrome by inducing an autoimmune response in which the immune system mistakenly attacks peripheral nerves, leading to inflammation and nerve damage. For example, in July 2024, according to a report published by the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based international organization, approximately 39.5 million people worldwide were living with HIV by the end of 2022, with 1.3 million new infections and 630,000 AIDS-related deaths reported during that year. In 2023, the global number of people living with HIV increased to around 39.9 million. Therefore, the increasing risk of immunological diseases is contributing to the growth of the Guillain-Barré syndrome market.

Rising healthcare expenditure is expected to further propel the growth of the Guillain-Barré syndrome market going forward. Healthcare expenditure refers to the total financial resources allocated by individuals, organizations, or governments toward the prevention, treatment, and management of health conditions. Spending on healthcare continues to increase due to advancements in medical technology, as new diagnostic tools, therapies, and innovative treatments often involve higher costs, leading to greater overall expenditure. Increased healthcare spending supports progress in Guillain-Barré syndrome management by enabling higher investment in early diagnosis, advanced immunotherapies, and enhanced critical care infrastructure, which together improve patient outcomes. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, healthcare expenditures in the United States rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. Therefore, rising healthcare expenditure is driving the growth of the Guillain-Barré syndrome market.

Major companies operating in the Guillain-Barré syndrome market are increasingly prioritizing innovative drug development, including monoclonal antibody therapies, to improve treatment effectiveness, address unmet clinical needs, and strengthen their market position. Monoclonal antibodies are laboratory-engineered proteins designed to target specific antigens, enabling precise modulation of immune responses and improved therapeutic outcomes. For example, in October 2023, Annexon Inc., a US-based biopharmaceutical company, received orphan drug designation from the European Medicines Agency (EMA) for its drug candidate ANX005 for the treatment of Guillain-Barré syndrome. ANX005 is a monoclonal antibody targeting C1q and has demonstrated early improvements in muscle strength along with a reduced need for mechanical ventilation compared with intravenous immunoglobulin (IVIg), highlighting its potential as a significant therapeutic advancement.

Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., CSL Behring, Hansa Biopharma AB, Annexon Inc., Immunovant Inc., UCB S.A., Alexion Pharmaceuticals, Argenx SE, Grifols S.A., LFB S.A.

North America was the largest region in the guillain-barre syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the guillain-barre syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the guillain-barre syndrome market by increasing costs of imported immunoglobulin products, plasma exchange equipment, diagnostic reagents, and neurological monitoring devices. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported biologics, while Asia-Pacific faces higher treatment costs for advanced therapies. These tariffs are increasing hospital procurement expenses and treatment affordability challenges. However, they are also supporting local plasma fractionation facilities, domestic production of immunotherapies, and regional supply chain resilience.

The guillain-barre syndrome market research report is one of a series of new reports that provides guillain-barre syndrome market statistics, including guillain-barre syndrome industry global market size, regional shares, competitors with a guillain-barre syndrome market share, detailed guillain-barre syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the guillain-barre syndrome industry. This guillain-barre syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Guillain-Barré syndrome is an uncommon neurological condition in which the body’s immune system erroneously targets the peripheral nervous system. This immune response can result in muscle weakness, numbness, tingling sensations, and in severe cases, paralysis. Although the precise cause is not fully understood, the condition is often triggered by infections such as respiratory or gastrointestinal illnesses, and in some cases by vaccinations or surgical procedures.

The main types of Guillain-Barré syndrome include acute inflammatory demyelinating polyneuropathy (AIDP), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Miller Fisher syndrome (MFS), acute motor axonal neuropathy (AMAN), and others. AIDP is an autoimmune condition in which the immune system attacks the myelin coverings of peripheral nerves, leading to inflammation and demyelination. Treatment options for GBS include intravenous immunoglobulin (IVIG), plasma exchange, and other supportive therapies. These treatments are primarily administered through parenteral and oral routes, and management occurs across various healthcare settings such as hospitals, clinics, diagnostic centers, and others.

The guillain-barre syndrome market consists of revenues earned by entities by providing services such as plasma exchange (plasmapheresis), intravenous immunoglobulin (IVIG) therapy, neurological diagnostic tests, and supportive care treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The guillain-barre syndrome market also includes sales of pharmaceutical drugs, immunotherapies, and diagnostic tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.